OmicsBank raises $2.25M seed led by Redesign Health to license Asian and US patient data to biopharma for AI-driven drug discovery.
August 25, 2026 09:00 AM EDT
Health Tech
Exclusive: OmicsBank raises $2.25M to bring overseas patient data to biopharma
Ngai Yeung
Health Tech Reporter
Traditional real-world datasets can create challenges for oncology evidence generation. Discover how Guardant Health's InfinityAI…
In this week’s edition of InnovationRx, we look at breakthroughs from ASCO, Harrison.ai's U.S. expansion, Clear's move into…
US biotechs turn tight-lipped on gene targets and pipelines as China's fast-follower threat intensifies, 20+ founders and…
Red-hot generative AI specialist Insilico Medicine has teamed up with another major biopharma player, this time linking up with…
AI is moving beyond experimentation in healthcare and life sciences. This free whitepaper explores how leading organizations are…
“We want to be the SpaceX of the pharmaceutical industry,” Alex Zhavoronkov, co-CEO of Insilico Medicine tells Fortune.
